Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Merck_&_Co.
|
| gptkbp:CEO |
gptkb:John_D._McKinley
|
| gptkbp:clinicalTrials |
withdrawn
ongoing completed pending suspended Phase 2 Phase 3 terminated recruiting Phase 1 trials active, not recruiting enrolling by invitation not yet recruiting |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:focusArea |
cancer therapeutics
|
| gptkbp:foundedIn |
2015
|
| gptkbp:founder |
gptkb:John_D._McKinley
|
| gptkbp:funding |
venture capital
Series A Series B Series C |
| gptkbp:headquarters |
gptkb:Dallas,_Texas
|
| https://www.w3.org/2000/01/rdf-schema#label |
Peloton Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPeople |
gptkb:Michael_A._McCarthy
gptkb:John_D._McKinley gptkb:David_A._Hyman |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:notableEvent |
PT2977
PT630 |
| gptkbp:partnerships |
gptkb:Merck_&_Co.
|
| gptkbp:research_areas |
neurology
autoimmune diseases hematology infectious diseases immunology urology |
| gptkbp:researchFocus |
oncology
HIF-2α inhibitors drug_discovery |
| gptkbp:supports |
small molecule inhibitors
|
| gptkbp:website |
www.pelotontherapeutics.com
|